Pentylenetetrazole - Balance Therapeutics
Alternative Names: BTD-001; carbon-14 (14C)-BTD-001; Pentetrazol; PTZLatest Information Update: 28 Jun 2020
At a glance
- Originator Balance Therapeutics
- Class Antihypotensives; Azepines; Nootropics; Respiratory stimulants; Sleep disorder therapies; Small molecules; Tetrazoles
- Mechanism of Action Central nervous system stimulants; GABA-A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Idiopathic hypersomnia; Narcolepsy
- No development reported Down syndrome
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for phase-I development in Down syndrome(In volunteers) in United Kingdom (PO)
- 04 Jun 2018 Balance Therapeutics plans the phase II ARISE2 trial for Idiopathic hypersomnia in USA in June 2018 (PO) (NCT03542851)
- 29 May 2018 Balance Therapeutics initiates the phase II ARISE2 trial for Idiopathic hypersomnia in USA (PO) (NCT03542851)